Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle

Volume: 5, Issue: 4, Pages: 549 - 551
Published: Jul 19, 2018
Abstract
A significant breakthrough in contemporary cardiometabolic medicine was the finding that some medications to treat type 2 diabetes mellitus (T2DM) are associated with reduced mortality and a lower risk of heart failure (HF) hospitalization when such patients have already established cardiovascular (CV) disease [EMPA-REG 1]. In the EMPA-REG OUTCOME trial, including 7020 patients with T2DM, established CV disease (not including HF as qualifying...
Paper Details
Title
Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
Published Date
Jul 19, 2018
Volume
5
Issue
4
Pages
549 - 551
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.